# Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

> **NCT05324592** · PHASE1 · COMPLETED · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** 9MW0813
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT05324592
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2021-09-24
- **Final completion:** 2022-01-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05324592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05324592, "Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05324592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*